Delighted to share that the remarkable work of Qing Yao, with contributions from my group and many others, has been published in Nature Microbiology. 🧪 #cryoEM
This study reveals, for the first time, the structure of the binding pocket of HSV helicase-primase inhibitors and their mode of action.
This study reveals, for the first time, the structure of the binding pocket of HSV helicase-primase inhibitors and their mode of action.
Structural and mechanistic insights into herpesvirus helicase–primase and its therapeutic inhibitors - Nature Microbiology
The cryo-EM structure of the herpes simplex virus helicase–primase (HP) complex informs about the mechanism of action of HP inhibitors pritelivir and amenamevir, which are drugs of clinical relevance.
www.nature.com
November 4, 2025 at 4:55 PM
Delighted to share that the remarkable work of Qing Yao, with contributions from my group and many others, has been published in Nature Microbiology. 🧪 #cryoEM
This study reveals, for the first time, the structure of the binding pocket of HSV helicase-primase inhibitors and their mode of action.
This study reveals, for the first time, the structure of the binding pocket of HSV helicase-primase inhibitors and their mode of action.
Thrilled to share the work of an incredible cross-functional team. 🧪
The article highlights the discovery and engineering of bispecific antibodies that demonstrated efficacy in a recurrent genital herpes in vivo model—the first such evidence for antibodies in this disease model.
The article highlights the discovery and engineering of bispecific antibodies that demonstrated efficacy in a recurrent genital herpes in vivo model—the first such evidence for antibodies in this disease model.
Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease
Lee et al. discovered cell-to-cell spread-blocking anti-HSV antibodies and engineered
them into potent bispecific antibodies that simultaneously target two glycoproteins
essential for viral entry and ...
www.cell.com
July 30, 2025 at 11:18 PM
Thrilled to share the work of an incredible cross-functional team. 🧪
The article highlights the discovery and engineering of bispecific antibodies that demonstrated efficacy in a recurrent genital herpes in vivo model—the first such evidence for antibodies in this disease model.
The article highlights the discovery and engineering of bispecific antibodies that demonstrated efficacy in a recurrent genital herpes in vivo model—the first such evidence for antibodies in this disease model.
Reposted by Alex Mercier
Submit your abstracts for the CMV symposium 2025 to be held in Sept near Frankfurt. Submission deadline is June 30. The top 3 abstracts will have travel and accommodation covered. Priority for excellent abstracts submitted by those earlier in their career. It will be a wonderful meeting! Join us!!
June 5, 2025 at 8:42 PM
Submit your abstracts for the CMV symposium 2025 to be held in Sept near Frankfurt. Submission deadline is June 30. The top 3 abstracts will have travel and accommodation covered. Priority for excellent abstracts submitted by those earlier in their career. It will be a wonderful meeting! Join us!!
Reposted by Alex Mercier
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
December 12, 2024 at 7:02 PM
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn